Photo by National Cancer Institute on Unsplash
I’ve bought this stock twice. Both buys are in the green. The first one is up 42%.
Then, this past Wednesday, one of the biggest banks on Wall Street cut it to Sell, with a price target roughly 60% below where the stock had just closed.
Thursday evening, it was named to the Nasdaq-100.
Same stock. Same week. Two completely opposite headlines. And this stock is already up more than 500% in 2026.
My model has never heard of either one. It doesn’t read analyst notes, and it doesn’t care about index announcements. Once a month, it re-scores 450+ stocks on fresh data. That’s all it did.
📅 In August, this stock landed at #4.
📅 In September, it climbed to #2.
📅 This month, it’s not #3.
It’s #1.
I’ve never bought the same stock three times. I’m about to.
First, how the last eight have done?
I’ve bought one QuantRank every week since Aug 10. Here’s every one, no cherry-picking, marked to Friday’s close:
Seven winners, one loser. The average across all eight is +14.16%, against +0.22% for SPY over the same holding periods. Five of those tickers are still locked above, including both of my earlier buys of this week’s stock.
Signal: BUY.
Capital stays invested — core and pick both.
Subscribe free to see this week’s pick and all 8 tickers, and get my future stocks in your inbox every Sunday at 6am ET.